Sex Differences in Midterm Prognostic Implications of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents in East Asian Patients: Results From the PTRG-DES (Platelet Function and Genotype-Related Long-Term...

Overview

Journal J Am Heart Assoc

Specialty Cardiology & Vascular Diseases

Date 2023 Apr 29

PMID 37119080

Authors

Soo-Jin Kim

Ae-Young Her

Young-Hoon Jeong

Byeong-Keuk Kim

Hyung Joon Joo

Yongwhi Park

Kiyuk Chang

Young Bin Song

Sung Gyun Ahn

Jung-Won Suh

Sang Yeub Lee

Jung Rae Cho

Hyo-Soo Kim

Moo Hyun Kim

Do-Sun Lim

Eun-Seok Shin

Affiliations

Soon will be listed here.

Abstract

Background Although high platelet reactivity (HPR) on clopidogrel is associated with higher ischemic events and lower bleeding events in patients who have undergone percutaneous coronary intervention with drug-eluting stents, the differential risk of HPR in East Asian women versus men is unknown. Methods and Results We compared 11 714 patients enrolled in the PTRG-DES (Platelet Function and Genotype-Related Long-Term Prognosis in Drug-Eluting Stent-Treated Patients With Coronary Artery Disease) Consortium according to sex and the presence/absence of HPR on clopidogrel (defined as ≥252 P2Y12 reactivity units). The primary study end point was major adverse cardiac and cerebrovascular events (MACCEs; comprising all-cause mortality, myocardial infarction, cerebrovascular accident, and stent thrombosis). HPR was more common in women (46.7%) than in men (28.1%). In propensity-adjusted models, HPR was an independent predictor of MACCEs (men with HPR: hazard ratio [HR], 1.60 [95% CI, 1.20-2.12]; women with HPR: HR, 0.99 [95% CI, 0.69-1.42]) and all-cause mortality (men with HPR: HR, 1.61 [95% CI, 1.07-2.44]; women with HPR: HR, 0.92 [95% CI, 0.57-1.50]) in men, although those associations were insignificant among women. In addition, a significant interaction between sex was noted in the associations between HPR and MACCE (=0.013) or all-cause mortality (=0.025). Conclusions In this study, HPR was a differential risk factor for 1-year MACCEs and all-cause mortality in women and men. And it was an independent predictor of 1-year MACCEs and all-cause mortality in men but not in women. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT04734028. Registered July 9, 2003, https://clinicaltrials.gov/ct2/show/NCT04734028.

References

Lansky A, Mehran R, Cristea E, Parise H, Feit F, Ohman E . Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). Am J Cardiol. 2009; 103(9):1196-203. DOI: 10.1016/j.amjcard.2009.01.030. View

Price M, Nayak K, Barker C, Kandzari D, Teirstein P . Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2009; 103(10):1339-43. DOI: 10.1016/j.amjcard.2009.01.341. View

Jastrzebska M, Marcinowska Z, Oledzki S, Chelstowski K, Siennicka A, Klysz M . Variable gender-dependent platelet responses to combined antiplatelet therapy in patients with stable coronary-artery disease. J Physiol Pharmacol. 2018; 69(4). DOI: 10.26402/jpp.2018.4.10. View

Moussa I, Klein L, Shah B, Mehran R, Mack M, Brilakis E . Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol. 2013; 62(17):1563-70. PMC: 3890321. DOI: 10.1016/j.jacc.2013.08.720. View

Lansky A, Pietras C, Costa R, Tsuchiya Y, Brodie B, Cox D . Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications.... Circulation. 2005; 111(13):1611-8. DOI: 10.1161/01.CIR.0000160362.55803.40. View

Staritz P, Kurz K, Stoll M, Giannitsis E, Katus H, Ivandic B . Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int J Cardiol. 2008; 133(3):341-5. DOI: 10.1016/j.ijcard.2007.12.118. View

Tantry U, Bonello L, Aradi D, Price M, Jeong Y, Angiolillo D . Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013; 62(24):2261-73. DOI: 10.1016/j.jacc.2013.07.101. View

Stone G, Witzenbichler B, Weisz G, Rinaldi M, Neumann F, Metzger D . Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013; 382(9892):614-23. DOI: 10.1016/S0140-6736(13)61170-8. View

Suh J, Lee S, Park K, Lee H, Kang H, Koo B . Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy.... J Am Coll Cardiol. 2011; 57(3):280-9. DOI: 10.1016/j.jacc.2010.08.631. View

10.

Her A, Jeong Y, Kim B, Joo H, Chang K, Park Y . Platelet Function and Genotype after DES Implantation in East Asian Patients: Rationale and Characteristics of the PTRG-DES Consortium. Yonsei Med J. 2022; 63(5):413-421. PMC: 9086699. DOI: 10.3349/ymj.2022.63.5.413. View

11.

Kovacic J, Mehran R, Karajgikar R, Baber U, Suleman J, Kim M . Female gender and mortality after percutaneous coronary intervention: results from a large registry. Catheter Cardiovasc Interv. 2011; 80(4):514-21. DOI: 10.1002/ccd.23338. View

12.

Bain B, Forster T . A sex difference in the bleeding time. Thromb Haemost. 1980; 43(2):131-2. View

13.

Lee S, Cha J, Jeong Y, Hong S, Ahn C, Kim J . Platelet Reactivity and Clinical Outcomes After Drug-Eluting Stent Implantation: Results From the PTRG-DES Consortium. JACC Cardiovasc Interv. 2022; 15(22):2253-2265. DOI: 10.1016/j.jcin.2022.09.007. View

14.

Mehran R, Pocock S, Nikolsky E, Clayton T, Dangas G, Kirtane A . A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010; 55(23):2556-66. DOI: 10.1016/j.jacc.2009.09.076. View

15.

Price M, Endemann S, Gollapudi R, Valencia R, Stinis C, Levisay J . Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008; 29(8):992-1000. DOI: 10.1093/eurheartj/ehn046. View

16.

Patti G, De Caterina R, Abbate R, Andreotti F, Biasucci L, Calabro P . Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper. Eur Heart J. 2014; 35(33):2213-23b. DOI: 10.1093/eurheartj/ehu279. View

17.

Yu J, Mehran R, Baber U, Ooi S, Witzenbichler B, Weisz G . Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Circ Cardiovasc Interv. 2017; 10(2). DOI: 10.1161/CIRCINTERVENTIONS.116.003577. View

18.

Garcia-Garcia H, McFadden E, Farb A, Mehran R, Stone G, Spertus J . Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Eur Heart J. 2018; 39(23):2192-2207. DOI: 10.1093/eurheartj/ehy223. View

19.

Moscucci M, Fox K, Cannon C, Klein W, Lopez-Sendon J, Montalescot G . Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003; 24(20):1815-23. DOI: 10.1016/s0195-668x(03)00485-8. View

20.

Aradi D, Kirtane A, Bonello L, Gurbel P, Tantry U, Huber K . Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015; 36(27):1762-71. DOI: 10.1093/eurheartj/ehv104. View